证券之星消息，12月1日南向资金减持391.6万股中国中药（00570.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持61.8万股。近20个交易日中，获南向资金减持的有11天，累计净减持270.6万 股。截至目前，南向资金持有中国中药（00570.HK）15.87亿股，占公司已发行普通股的31.51%。 中国中药控股有限公司是一家主要从事中药制造及销售的投资控股公司。该公司通过四个分部运营业 务。一方分部主要从事中药配方颗粒、中药大健康产品及中药饮片的生产及销售。天江分部主要从事中 药配方颗粒、中药饮片及中药大健康产品的生产及销售。该分部还透过其线下医疗机构提供中医药相关 的医疗保健解决方案,包括中医问诊诊断、中医理疗、中药配方颗粒处方药等产品。同济堂分部主要从 事中药配方颗粒、中药饮片及中成药的生产及销售。该分部还从事大健康产业的各种大健康产品的生产 及销售及透过线下医疗机构提供中药医疗保健解决方案。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | ...

Group 1 - The core point of the news is that southbound funds have increased their holdings in China Traditional Chinese Medicine (00570.HK) significantly, with a total net increase of 14.23 million shares over the last five trading days and 40.55 million shares over the last twenty trading days [1][2] - As of October 22, 2025, southbound funds hold a total of 1.598 billion shares of China Traditional Chinese Medicine, representing 31.72% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show fluctuations, with a notable increase of 1.3292 million shares on October 21, 2025, and a decrease of 1.0828 million shares on October 17, 2025 [2] Group 2 - China Traditional Chinese Medicine Holdings Limited primarily engages in the manufacturing and sales of traditional Chinese medicine through four business segments [2] - The business segments include the production and sales of traditional Chinese medicine formula granules, health products, and decoction pieces, along with providing healthcare solutions through offline medical institutions [2]